Trial reportBritish journal of cancer2004
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.
Trial report in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 40 citations in OpenAlex.
- Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications.Discover oncology · 2025Review
- Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System.Frontiers in oncology · 2019Review
- A novel computational approach for drug repurposing using systems biology.Bioinformatics (Oxford, England) · 2018Article
- Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Science translational medicine · 2017Review
- An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types.Bioinformatics (Oxford, England) · 2016Article
- Article
- Amelioration of an undesired action of deguelin.Toxicon : official journal of the International Society on Toxinology · 2013Article
- Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.Journal of cancer research and clinical oncology · 2009Article
- Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.British journal of cancer · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the combination of these drugs in patients with advanced cancer. In all, 50 patients were enrolled. Captopril was given orally at a dose of 50 mg bd daily. Fragmin was administered as a daily subcutaneous injection of 200 units kg(-1) for the first 28 days and 5000 units thereafter. Marimastat was given at 10 mg bd orally. Serum, plasma and urinary angiogenic factors were measured at baseline and after 1 month of treatment. Inhibition of release of tumour necrosis factor alpha (TNF-alpha) from peripheral lymphocytes was used as a surrogate pharmacodynamic end point. There was one case of haemorrhagic stroke and one upper gastrointestinal haemorrhage. The commonest toxicity was myalgia. One of 10 patients with renal cancer had a partial response, and three patients had a prolonged period of stable disease. The treatment significantly inhibited phytohaemagglutinin (PHA)-stimulated TNF-alpha release from patient's lymphocytes. The combination of marimastat, fragmin and captopril is well tolerated and has in vivo activity. Inhibition of PHA-stimulated TNF-alpha release from lymphocytes is a surrogate pharmacodynamic marker of metalloprotease inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.